DRI Healthcare Trust (TSE:DHT.UN) Given Average Rating of “Moderate Buy” by Analysts

DRI Healthcare Trust (TSE:DHT.UN) has been given an average recommendation of “Moderate Buy” by the six research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is C$18.00.

DHT.UN has been the subject of several analyst reports. Raymond James cut their target price on DRI Healthcare Trust from C$23.00 to C$22.00 in a research note on Wednesday, November 13th. Scotiabank raised their target price on DRI Healthcare Trust from C$21.00 to C$22.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th.

DRI Healthcare Trust Stock Performance

Shares of TSE DHT.UN opened at C$12.75 on Thursday. DRI Healthcare Trust has a 52 week low of C$10.39 and a 52 week high of C$17.43. The business has a 50-day simple moving average of C$13.46 and a two-hundred day simple moving average of C$13.33.

DRI Healthcare Trust Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 18th. Stockholders of record on Friday, October 18th were given a dividend of $0.085 per share. The ex-dividend date was Friday, September 27th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 2.67%. DRI Healthcare Trust’s dividend payout ratio (DPR) is presently -920.00%.

About DRI Healthcare Trust

DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.